|
WO1988008854A1
(en)
|
1987-05-06 |
1988-11-17 |
Egbert Oosterwijk |
Monoclonal antibodies to renal cell carcinoma
|
|
WO1989006544A1
(en)
|
1988-01-15 |
1989-07-27 |
Centocor, Inc. |
Heteroligating antibodies and therapeutic uses thereof
|
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
WO1993017715A1
(en)
|
1992-03-05 |
1993-09-16 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
|
US6036955A
(en)
|
1992-03-05 |
2000-03-14 |
The Scripps Research Institute |
Kits and methods for the specific coagulation of vasculature
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
|
US5622701A
(en)
|
1994-06-14 |
1997-04-22 |
Protein Design Labs, Inc. |
Cross-reacting monoclonal antibodies specific for E- and P-selectin
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
AU5509296A
(en)
|
1995-05-03 |
1996-11-21 |
Colin Henry Self |
Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety
|
|
DE19531346A1
(de)
|
1995-08-25 |
1997-02-27 |
Gsf Forschungszentrum Umwelt |
Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
JP4169478B2
(ja)
|
1998-04-21 |
2008-10-22 |
マイクロメット アーゲー |
Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用
|
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
|
DK1124568T3
(da)
|
1998-10-21 |
2008-01-02 |
Altor Bioscience Corp |
Polyspecifikke bindingsmolekyler og anvendelser deraf
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CN1423700A
(zh)
|
2000-03-24 |
2003-06-11 |
麦克美特股份公司 |
含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
|
|
US20020103345A1
(en)
|
2000-05-24 |
2002-08-01 |
Zhenping Zhu |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
US20040115198A1
(en)
|
2001-02-28 |
2004-06-17 |
Fred Hutchinson Cancer Research Center |
Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
|
|
US20020193569A1
(en)
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
|
DE10156482A1
(de)
|
2001-11-12 |
2003-05-28 |
Gundram Jung |
Bispezifisches Antikörper-Molekül
|
|
UA87979C2
(ru)
|
2002-08-19 |
2009-09-10 |
Астразенека Аб |
Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
DE10261223A1
(de)
|
2002-12-20 |
2004-07-08 |
MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH |
Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen
|
|
JP2007523602A
(ja)
|
2003-02-06 |
2007-08-23 |
マイクロメット アクツィエン ゲゼルシャフト |
持続的なｔ細胞応答方法
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
WO2004106381A1
(en)
|
2003-05-31 |
2004-12-09 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
|
US8784821B1
(en)
|
2003-05-31 |
2014-07-22 |
Amgen Research (Munich) Gmbh |
Human-anti-human cd3 binding molecules
|
|
CA2532547C
(en)
|
2003-07-24 |
2020-02-25 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
DK1716178T3
(da)
|
2004-02-16 |
2010-09-20 |
Micromet Ag |
Mindre immunogene bindingsmolekyler
|
|
NZ552745A
(en)
|
2004-07-16 |
2009-01-31 |
Micromet Ag |
Expression-enhanced polypeptides
|
|
KR20190126461A
(ko)
|
2004-07-22 |
2019-11-11 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
EP1809669A2
(en)
|
2004-10-01 |
2007-07-25 |
Avidex Ltd |
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
WO2006113665A2
(en)
|
2005-04-15 |
2006-10-26 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2010080538A1
(en)
|
2008-12-19 |
2010-07-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US20070071759A1
(en)
|
2005-06-29 |
2007-03-29 |
University Of Miami |
Antibody-immune cell ligand fusion protein for cancer therapy
|
|
JP2009504787A
(ja)
|
2005-08-19 |
2009-02-05 |
シーラス コーポレイション |
抗体によって媒介される免疫応答の増強
|
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
|
WO2007042261A2
(en)
|
2005-10-11 |
2007-04-19 |
Micromet Ag |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
EP2322557B1
(en)
|
2005-10-14 |
2017-08-30 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
JP2009513608A
(ja)
|
2005-10-28 |
2009-04-02 |
ノボ・ノルデイスク・エー／エス |
エフェクターリンパ球と標的細胞とを結合する融合タンパク質
|
|
JP2009514537A
(ja)
|
2005-11-03 |
2009-04-09 |
ジェネンテック・インコーポレーテッド |
治療的抗ｈｅｒ２抗体融合ポリペプチド
|
|
JP2009514528A
(ja)
|
2005-11-03 |
2009-04-09 |
フレッド ハッチンソン キャンサー リサーチ センター |
Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
|
|
PT1976886E
(pt)
|
2005-12-16 |
2015-03-09 |
Amgen Res Munich Gmbh |
Meios e processos para o tratamento de doenças tumorais
|
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
|
AU2007257692B2
(en)
|
2006-06-12 |
2013-11-14 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
MY170607A
(en)
|
2006-09-07 |
2019-08-20 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
|
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
|
WO2008143954A2
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
EP2014680A1
(en)
|
2007-07-10 |
2009-01-14 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
|
|
US8119130B2
(en)
|
2007-07-25 |
2012-02-21 |
Medimmune Limited |
Targeted binding agents directed to KDR and uses thereof—035
|
|
WO2009023270A2
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
EP3753947A1
(en)
|
2007-09-14 |
2020-12-23 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
PL2222706T5
(pl)
|
2007-12-14 |
2017-09-29 |
Novo Nordisk As |
Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania
|
|
WO2009089004A1
(en)
|
2008-01-07 |
2009-07-16 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
EP2245066A2
(en)
|
2008-01-22 |
2010-11-03 |
Biogen Idec MA Inc. |
Ron antibodies and uses thereof
|
|
EP2297208A4
(en)
|
2008-06-03 |
2012-07-11 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
|
US8067339B2
(en)
|
2008-07-09 |
2011-11-29 |
Merck Sharp & Dohme Corp. |
Surface display of whole antibodies in eukaryotes
|
|
WO2010017103A2
(en)
|
2008-08-04 |
2010-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Fully human anti-human nkg2d monoclonal antibodies
|
|
JP2012503490A
(ja)
|
2008-09-26 |
2012-02-09 |
ワイス・エルエルシー |
単鎖抗体ライブラリー設計
|
|
DK2356270T3
(da)
|
2008-11-07 |
2016-12-12 |
Fabrus Llc |
Kombinatoriske antistofbiblioteker og anvendelser deraf
|
|
ES2550384T3
(es)
|
2008-12-18 |
2015-11-06 |
Dana-Farber Cancer Institute, Inc. |
NKG2D-Fc para la inmunoterapia
|
|
BRPI1012589A2
(pt)
|
2009-04-07 |
2016-03-22 |
Roche Glycart Ag |
anticorpos bi-específicos anti-erbb-3/anti-c-met
|
|
US20120058082A1
(en)
|
2009-05-13 |
2012-03-08 |
Genzyme Corporation |
Methods and compositions for treatment
|
|
US20130209514A1
(en)
|
2009-06-09 |
2013-08-15 |
Eli Gilboa |
Aptamer-targeted costimulatory ligand aptamer
|
|
SG177560A1
(en)
|
2009-07-06 |
2012-03-29 |
Hoffmann La Roche |
Bi-specific digoxigenin binding antibodies
|
|
TW201109438A
(en)
|
2009-07-29 |
2011-03-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US9062287B2
(en)
|
2009-09-11 |
2015-06-23 |
Takara Bio Inc. |
Process for production of natural killer cells
|
|
US8840888B2
(en)
|
2009-10-27 |
2014-09-23 |
Micromet Ag |
Dosage regimen for administering a CD19XCD3 bispecific antibody
|
|
US8999398B2
(en)
|
2009-11-06 |
2015-04-07 |
Transtarget Inc. |
Polyclonal bispecific antibody compositions and method of use
|
|
EP2332994A1
(en)
|
2009-12-09 |
2011-06-15 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Trispecific therapeutics against acute myeloid leukaemia
|
|
US20120288507A1
(en)
|
2009-12-18 |
2012-11-15 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
US8796420B2
(en)
|
2009-12-31 |
2014-08-05 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
US8658765B2
(en)
|
2009-12-31 |
2014-02-25 |
Avidbiotics Corp. |
Non-natural MIC proteins
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12018501083A1
(en)
|
2010-03-04 |
2019-02-18 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究（慕尼黑）有限責任公司 |
跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
US9527926B2
(en)
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
DE102010039018B4
(de)
|
2010-08-06 |
2013-02-28 |
Technische Universität Dresden |
Anti-La Antikörper und ihre Anwendung zum Immunotargeting
|
|
EP2603526A1
(en)
|
2010-08-13 |
2013-06-19 |
Medimmune Limited |
Monomeric polypeptides comprising variant fc regions and methods of use
|
|
EP2609111B1
(en)
|
2010-08-24 |
2017-11-01 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising a disulfide stabilized-fv fragment
|
|
TWI560199B
(en)
|
2010-08-31 |
2016-12-01 |
Sanofi Sa |
Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
JP5866130B2
(ja)
|
2010-09-10 |
2016-02-17 |
アペクシジェン， インコーポレイテッド |
抗ＩＬ−１β抗体およびその使用方法
|
|
AR083705A1
(es)
|
2010-11-04 |
2013-03-13 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
RS59589B1
(sr)
|
2010-11-05 |
2019-12-31 |
Zymeworks Inc |
Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
|
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
CN112812184A
(zh)
|
2011-02-25 |
2021-05-18 |
中外制药株式会社 |
FcγRIIb特异性Fc抗体
|
|
AU2012229048B2
(en)
|
2011-03-16 |
2016-01-21 |
Amgen Inc |
Fc variants
|
|
SG10201602371VA
(en)
|
2011-03-25 |
2016-04-28 |
Glenmark Pharmaceuticals Sa |
Hetero-dimeric immunoglobulins
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
EP2714079B2
(en)
|
2011-05-21 |
2019-08-28 |
MacroGenics, Inc. |
Deimmunized serum-binding domains and their use for extending serum half-life
|
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
EP2723362A1
(en)
|
2011-06-21 |
2014-04-30 |
Innate Pharma |
NKp46-MEDIATED NK CELL TUNING
|
|
TWI687441B
(zh)
*
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
DE102011118022B4
(de)
|
2011-06-30 |
2018-01-18 |
Gemoab Monoclonals Gmbh |
Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung
|
|
CA2842649C
(en)
|
2011-07-22 |
2020-01-21 |
Affimed Therapeutics Ag |
Multivalent antigen-binding fv molecule
|
|
WO2013036799A2
(en)
|
2011-09-09 |
2013-03-14 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving nkg2d inhibitors and cancer
|
|
SG11201401102VA
(en)
|
2011-09-30 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Ion concentration-dependent binding molecule library
|
|
US20150050269A1
(en)
|
2011-09-30 |
2015-02-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
BR112014015018A2
(pt)
*
|
2011-12-19 |
2020-10-27 |
Synimmune Gmbh |
moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico
|
|
US10633451B2
(en)
|
2012-02-03 |
2020-04-28 |
Hoffmann-La Roche Inc. |
Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
|
|
AU2013200903B2
(en)
|
2012-02-08 |
2015-05-14 |
Mcure Biosciences Inc. |
CDIM binding proteins and uses thereof
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
US9029510B2
(en)
|
2012-03-30 |
2015-05-12 |
Sorrento Therapeutics, Inc. |
Fully human antibodies that bind to VEGFR2 and methods of use thereof
|
|
CA2870821C
(en)
|
2012-04-20 |
2022-06-14 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
|
CN107759686A
(zh)
|
2012-05-30 |
2018-03-06 |
中外制药株式会社 |
靶组织特异性抗原结合分子
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
US10377827B2
(en)
*
|
2012-06-21 |
2019-08-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
|
AU2013289883B2
(en)
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
|
CN104640561A
(zh)
|
2012-07-23 |
2015-05-20 |
酵活有限公司 |
包含轻链和重链的选择性配对的免疫球蛋白构建体
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
LT2900694T
(lt)
*
|
2012-09-27 |
2018-11-12 |
Merus N.V. |
Bispecifiniai igg antikūnai kaip t ląstelių aktyvatoriai
|
|
CN104271602B
(zh)
|
2012-11-21 |
2020-08-21 |
武汉友芝友生物制药有限公司 |
双特异性抗体
|
|
KR101522954B1
(ko)
|
2012-11-27 |
2015-05-27 |
아주대학교산학협력단 |
항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
|
|
ES2984345T3
(es)
|
2013-01-10 |
2024-10-29 |
Genmab Bv |
Variantes de la región FC de IGG1 humana y usos de las mismas
|
|
DK2943511T3
(da)
|
2013-01-14 |
2019-10-21 |
Xencor Inc |
Nye heterodimeriske proteiner
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US20140242077A1
(en)
|
2013-01-23 |
2014-08-28 |
Abbvie, Inc. |
Methods and compositions for modulating an immune response
|
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
|
WO2014124326A1
(en)
|
2013-02-08 |
2014-08-14 |
Stem Centrx, Inc. |
Novel multispecific constructs
|
|
PT2961771T
(pt)
|
2013-02-26 |
2020-02-28 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
|
|
PL2968520T3
(pl)
|
2013-03-14 |
2022-01-03 |
Macrogenics, Inc. |
Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego
|
|
EP3587448B1
(en)
|
2013-03-15 |
2021-05-19 |
Xencor, Inc. |
Heterodimeric proteins
|
|
AU2014228772B2
(en)
|
2013-03-15 |
2019-02-28 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
|
US20140323315A1
(en)
|
2013-04-29 |
2014-10-30 |
Adimab, Llc |
Polyspecificity reagents, methods for their preparation and use
|
|
US10077312B2
(en)
|
2013-05-10 |
2018-09-18 |
Numab Therapeutics AG |
CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
|
|
US10174117B2
(en)
|
2013-06-11 |
2019-01-08 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer
|
|
US9908944B2
(en)
|
2013-07-15 |
2018-03-06 |
Novo Nordisk A/S |
Antibodies that bind urokinase plasminogen activator
|
|
MX384142B
(es)
|
2013-07-16 |
2025-03-14 |
Genentech Inc |
Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer.
|
|
RU2727836C2
(ru)
|
2013-07-25 |
2020-07-24 |
Сайтомкс Терапьютикс, Инк. |
Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
|
|
CN111606998B
(zh)
|
2013-09-16 |
2024-05-24 |
健康与环境慕尼黑德国研究中心赫姆霍茨中心（有限责任公司） |
用于治疗hbv感染和相关病症的双或多特异性多肽
|
|
GB2518221A
(en)
|
2013-09-16 |
2015-03-18 |
Sergej Michailovic Kiprijanov |
Tetravalent antigen-binding protein molecule
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
EP3066130B1
(en)
|
2013-11-07 |
2019-05-15 |
Memorial Sloan-Kettering Cancer Center |
Anti-wt1/hla bi-specific antibody
|
|
DE102013019352A1
(de)
|
2013-11-13 |
2015-09-17 |
Elke Pogge Von Strandmann |
Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort
|
|
TW201533060A
(zh)
|
2013-12-13 |
2015-09-01 |
Genentech Inc |
抗ｃｄ３３抗體及免疫結合物
|
|
WO2015095412A1
(en)
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
|
EP3083682B1
(en)
|
2013-12-20 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Dual specific antibodies
|
|
EP3083696B1
(en)
|
2013-12-20 |
2018-02-14 |
F.Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
|
RU2016129724A
(ru)
|
2013-12-23 |
2018-01-30 |
Займворкс Инк. |
Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения
|
|
DK3089994T3
(da)
|
2013-12-30 |
2022-07-04 |
Epimab Biotherapeutics Inc |
Fabs-in-tandem-immunglobulin og anvendelser deraf
|
|
BR112016016114A2
(pt)
|
2014-01-15 |
2018-05-22 |
Zymeworks Inc |
Construtos de ligação a antígeno cd19 e cd3 bi- específico.
|
|
PL3241561T3
(pl)
|
2014-03-05 |
2025-09-01 |
Autolus Limited |
Skoniugowane przeciwciało lub bi-specyficzny środek angażujący komórki T, które selektywnie wiążą region stały 1 TCR beta (TRBC1) lub TRBC2
|
|
CA2943834A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
EP3126384B1
(en)
|
2014-04-01 |
2020-12-02 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
CN112759650B
(zh)
|
2014-04-03 |
2024-10-01 |
Igm生物科学股份有限公司 |
修饰的j链
|
|
BR112016022910A2
(pt)
|
2014-04-11 |
2017-10-17 |
Medimmune Llc |
anticorpos contra her2 biespecíficos
|
|
EP2930188A1
(en)
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
EP2942629A1
(en)
|
2014-05-08 |
2015-11-11 |
Universität Würzburg |
Predictive markers for successful cancer immunotherapy
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
WO2015197582A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Monomeric multispecific antigen binding proteins
|
|
EP3161002A1
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
|
WO2015197598A2
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
EP3164417A1
(en)
|
2014-07-01 |
2017-05-10 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
WO2016011571A1
(en)
|
2014-07-21 |
2016-01-28 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell
|
|
US9777073B2
(en)
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
CN107106677A
(zh)
|
2014-08-28 |
2017-08-29 |
莱顿大学学术医院以Lumc的名义运作 |
Cd94/nkg2a和/或cd94/nkg2b抗体、疫苗组合
|
|
ES2688035T3
(es)
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
AU2015342264B2
(en)
|
2014-11-03 |
2021-08-12 |
Merck Patent Gmbh |
Methods for generating bispecific shark variable antibody domains and use thereof
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
ES2907467T3
(es)
|
2014-12-05 |
2022-04-25 |
Xyphos Biosciences Inc |
Fragmentos variables insertables de anticuerpos y dominios a1-a2 modificados de ligandos NKG2D
|
|
WO2016100533A2
(en)
|
2014-12-17 |
2016-06-23 |
Intrexon Corporation |
Intercalated single-chain variable fragments
|
|
CA2970986C
(en)
|
2014-12-19 |
2021-10-26 |
Biotecnol Limited |
Fusion protein comprising three binding domains to 5t4 and cd3
|
|
CA2972800A1
(en)
|
2015-01-02 |
2016-07-07 |
Dyax Corp. |
Bispecific antibodies against plasma kallikrein and factor xii
|
|
JP2018503399A
(ja)
|
2015-01-14 |
2018-02-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
多特異性免疫調節抗原結合構築物
|
|
AR100680A1
(es)
*
|
2015-01-26 |
2016-10-26 |
Macrogenics Inc |
Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos
|
|
WO2016134371A2
(en)
|
2015-02-20 |
2016-08-25 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
|
MA41613A
(fr)
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
US11673957B2
(en)
|
2015-03-10 |
2023-06-13 |
Eureka Therapeutics, Inc. |
Anti-ROR2 antibodies
|
|
RU2733496C2
(ru)
|
2015-03-16 |
2020-10-02 |
Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
|
|
CN114456272A
(zh)
|
2015-04-03 |
2022-05-10 |
优瑞科生物技术公司 |
靶向afp肽/mhc复合体的构建体及其用途
|
|
DK3280432T3
(da)
|
2015-04-06 |
2021-04-26 |
Subdomain Llc |
Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
|
|
MX393951B
(es)
|
2015-04-07 |
2025-03-24 |
Alector Llc |
Anticuerpos antisortilina y métodos para su uso.
|
|
TWI703159B
(zh)
|
2015-04-13 |
2020-09-01 |
美商輝瑞股份有限公司 |
Bcma特異性治療性抗體及其用途
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
EP3297671A4
(en)
|
2015-05-18 |
2019-02-06 |
Eureka Therapeutics, Inc. |
ANTI-ROR1 ANTIBODY
|
|
EP3095792A1
(en)
|
2015-05-19 |
2016-11-23 |
Klinikum rechts der Isar der Technischen Universität München |
T cell receptor with specificity for myeloperoxidase peptide and uses thereof
|
|
WO2016191305A1
(en)
|
2015-05-22 |
2016-12-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Btn3a ectodomain proteins and methods of use
|
|
HUE050750T2
(hu)
|
2015-05-29 |
2021-01-28 |
Agenus Inc |
CTLA-4 elleni antitestek és eljárások alkalmazásukra
|
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｏｘ４０に対する抗体およびその使用
|
|
HK1252675A1
(zh)
|
2015-06-12 |
2019-05-31 |
Alector Llc |
抗cd33抗体及其使用方法
|
|
CN107708741A
(zh)
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
AU2016284866B2
(en)
*
|
2015-06-23 |
2022-09-29 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
|
US10344081B2
(en)
|
2015-07-06 |
2019-07-09 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
WO2017011342A1
(en)
|
2015-07-10 |
2017-01-19 |
Abbvie Inc. |
Igm-or-ige-modified binding proteins and uses thereof
|
|
WO2017008169A1
(en)
|
2015-07-15 |
2017-01-19 |
Zymeworks Inc. |
Drug-conjugated bi-specific antigen-binding constructs
|
|
AU2016293606A1
(en)
|
2015-07-16 |
2018-02-08 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
CA2998589A1
(en)
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
|
|
AU2016329120B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for a costimulatory TNF receptor
|
|
CA3003458A1
(en)
|
2015-10-29 |
2017-05-04 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
|
BR112018009129A2
(pt)
|
2015-11-04 |
2019-02-26 |
J. PRICEMAN Saul |
receptores de antígeno quimérico que visam her2
|
|
US10815290B2
(en)
|
2015-11-10 |
2020-10-27 |
Fred Hutchinson Cancer Research Center |
NKG2D decoys
|
|
US20180327499A1
(en)
|
2015-11-13 |
2018-11-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti- nkg2d single domain antibodies and uses thereof
|
|
AU2016383475B2
(en)
|
2015-12-28 |
2024-02-22 |
Innate Pharma |
Variable regions for NKp46 binding proteins
|
|
EP3402519A4
(en)
*
|
2016-01-13 |
2020-01-08 |
Compass Therapeutics LLC |
Multispecific immunomodulatory antigen-binding constructs
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
WO2017142928A1
(en)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Ror1-binding molecules, and methods of use thereof
|
|
AU2017222700B2
(en)
|
2016-02-26 |
2018-09-27 |
Imunexus Therapeutics Limited |
Multi-specific molecules
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN109153727A
(zh)
|
2016-04-15 |
2019-01-04 |
酵活有限公司 |
靶向免疫治疗剂的多特异性抗原结合构建体
|
|
EP3442574A4
(en)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
|
|
GB201610044D0
(en)
|
2016-06-08 |
2016-07-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
CN105906722B
(zh)
|
2016-06-24 |
2020-02-07 |
安徽未名细胞治疗有限公司 |
一种Her2特异性嵌合抗原受体及其应用
|
|
US20200048347A1
(en)
|
2016-09-01 |
2020-02-13 |
Immunomab, Inc. |
Bispecific antibodies
|
|
WO2018071777A1
(en)
|
2016-10-14 |
2018-04-19 |
Harpoon Therapeutics, Inc. |
Innate immune cell trispecific binding proteins and methods of use
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
JP2020506971A
(ja)
|
2017-02-08 |
2020-03-05 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
|
|
WO2018148447A1
(en)
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
MY205850A
(en)
|
2017-02-10 |
2024-11-15 |
Dragonfly Therapeutics Inc |
Proteins binding bcma, nkg2d and cd16
|
|
EP3579878A4
(en)
|
2017-02-10 |
2020-11-18 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING PSMA, NKG2D AND CD16
|
|
MX2019009847A
(es)
|
2017-02-20 |
2019-12-19 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a cd123, nkg2d y cd16.
|
|
KR20190120783A
(ko)
|
2017-02-20 |
2019-10-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Gd2, nkg2d 및 cd16에 결합하는 단백질
|
|
SG11201907646YA
(en)
|
2017-02-20 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Proteins binding her2, nkg2d and cd16
|
|
US20210130471A1
(en)
|
2017-02-20 |
2021-05-06 |
Dragonfly Therapeutics, Inc. |
Proteins binding cd33, nkg2d and cd16
|
|
SG10202011219YA
(en)
|
2017-02-27 |
2020-12-30 |
Dragonfly Therapeutics Inc |
Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20200157174A1
(en)
|
2017-05-23 |
2020-05-21 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and ror1 or ror2
|
|
EP3630181A4
(en)
|
2017-05-23 |
2021-03-17 |
Dragonfly Therapeutics, Inc. |
NKG2D BINDING PROTEIN, CD16 AND TUMOR ASSOCIATED ANTIGEN
|
|
CN111278455A
(zh)
|
2017-05-23 |
2020-06-12 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
AU2018309712A1
(en)
|
2017-07-31 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and FLT3
|
|
CA3176049A1
(en)
|
2017-08-16 |
2019-02-21 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
|
|
BR112020003654A2
(pt)
|
2017-08-23 |
2020-11-17 |
Dragonfly Therapeutics, Inc. |
proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor
|
|
KR20240167101A
(ko)
|
2017-09-07 |
2024-11-26 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 넥틴4에 결합하는 단백질
|
|
MA50255A
(fr)
|
2017-09-14 |
2021-05-26 |
Dragonfly Therapeutics Inc |
Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
|
|
PE20210375A1
(es)
|
2018-02-08 |
2021-03-02 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
|
|
FI3749346T3
(fi)
|
2018-02-08 |
2024-09-04 |
Dragonfly Therapeutics Inc |
Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
|
|
SG11202007943RA
(en)
|
2018-02-20 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting cd33, and use thereof
|
|
MX2020008684A
(es)
|
2018-02-20 |
2020-12-07 |
Dragonfly Therapeutics Inc |
Proteinas de union multiespecificas que se unen a cd33, nkg2d y cd16 y metodos de uso.
|
|
US20210221894A1
(en)
|
2018-04-03 |
2021-07-22 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
WO2019195408A1
(en)
|
2018-04-03 |
2019-10-10 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
|
CN112437672A
(zh)
|
2018-05-07 |
2021-03-02 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
CA3100234A1
(en)
|
2018-05-16 |
2019-11-21 |
Dragonfly Therapeutics, Inc. |
Protein binding nkg2d, cd16 and a fibroblast activation protein
|
|
EA202091977A1
(ru)
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
MX2021001510A
(es)
|
2018-08-08 |
2021-07-02 |
Dragonfly Therapeutics Inc |
Proteínas de union a nkg2d, cd16, y un antígeno asociado a tumores.
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
TWI891611B
(zh)
|
2018-10-23 |
2025-08-01 |
美商蜻蜓醫療公司 |
異二聚體fc融合蛋白
|
|
JP2022520978A
(ja)
|
2019-02-18 |
2022-04-04 |
クーリエ セラピューティクス インコーポレイテッド |
オルソポックスウイルス主要組織適合性複合体（ｍｈｃ）クラスｉ様タンパク質（ｏｍｃｐ）と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質
|
|
NZ783169A
(en)
|
2019-06-25 |
2024-12-20 |
Gilead Sciences Inc |
Flt3l-fc fusion proteins and methods of use
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
WO2021041878A1
(en)
|
2019-08-30 |
2021-03-04 |
Dragonfly Therapeutics, Inc. |
Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
|
|
TW202208428A
(zh)
|
2020-05-06 |
2022-03-01 |
美商蜻蜓醫療公司 |
結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質
|